Prosthetic (Prosthesis) devices, such as an artificial leg, that replace a part of the body. Prostheses are typically used to replace parts lost by injury (traumatic) or missing from birth (congenital) or to supplement defective body parts. Inside the body, artificial heart valves are in common use with artificial hearts and lungs seeing less common use but under active technology development. Other medical devices and aids that can be considered prosthetics include artificial eyes, palatal obturator, gastric bands, and dentures.
CryoLife, Inc. an implantable biological medical device and cardiovascular tissue processing company, today announced that its BioGlue Surgical Adhesive has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for use in the repair of aortic dissections.
Covidien, a leading global provider of healthcare products, will preview new devices and showcase some of the Company's most innovative products at the 96th Annual Clinical Congress of the American College of Surgeons.
Kaiser Health News: "A little-noticed section in the health-care overhaul aims to raise awareness among young women and their doctors about the risk of breast cancer between the ages of 15 and 44. The law directs the Centers for Disease Control and Prevention to create education campaigns that will focus on breast cancer and young women, and encourage healthful habits that promote prevention and early detection of the disease.
PolyTouch Medical Ltd., a leading developer of laparoscopic soft tissue prosthetic placement technologies, announced today that the Company has raised US $830k in a private financing round.
Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives, according to a new multicenter study, to be published online at 2 p.m. Pacific time today in the New England Journal of Medicine.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted two United States patents for its total disc replacement (TDR) technology that features the use of silicon nitride in the construction of the complete implant.
The light, tickling tread of a pesky fly landing on your face may strike most of us as one of the most aggravating of life's small annoyances. But for scientists working to develop pressure sensors for artificial skin for use on prosthetic limbs or robots, skin sensitive enough to feel the tickle of fly feet would be a huge advance. Now Stanford researchers have built such a sensor.
ADA Technologies, Inc.'s PhysioNetics division has been awarded an $815,000 grant from the National Institutes of Health, National Institute of Child Health and Human Development. The Phase II award will enable PhysioNetics to complete design refinements and commercialization activities for its low-cost upper-extremity prosthetic interface, also known as a "socket."
Lightning fast connections between robotic limbs and the human brain may be within reach for injured soldiers and other amputees with the establishment of a multimillion-dollar research center led by SMU engineers.
Genetically closely related skin bacteria that have developed resistance to several different antibiotics and that can cause intractable care-related infections are found and seem to be spreading within and between hospitals in Sweden.
Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,776,085 B2, covering an improved knee implant prosthesis that features a monoblock ceramic tibial component for articulation with natural or prosthetic (resurfaced) femoral surfaces.
Christian Kandlbauer, who lost both of his arms in a high voltage accident, uses a unique development which until recently sounded almost like science fiction: An arm prosthesis, the first of its kind in the world, which he controls solely through the power of his mind.
When Doris Snyder celebrated her 102nd birthday on August 10, she was that much closer to the expected birth of her first great-granddaughter who's due to arrive early September. She is very excited about the milestone, which might not have been possible were it not for a cutting-edge, experimental procedure that replaced one of Doris' heart valves weeks earlier when she was 101. The valve had been rendered useless by aortic valve stenosis—hardening from calcium deposits that restrict the flow of blood from the heart.
Atrium Medical Corporation was recently named as a defendant, along with Endologix, Inc., of Irvine, CA, in a lawsuit brought by C.R. Bard in U.S. District Court in Arizona. The suit involves a patent, U.S. No. 6,436,135, issued to Bard in 2002 related to prosthetic vascular grafts made of ePTFE (expanded polytetrafluoroethylene). Atrium has been involved in discussions with Bard management regarding this patent for several years.
W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, responded to the Bard Peripheral Vascular, Inc. lawsuit filed against Endologix in the United States District Court of Arizona. The Bard Peripheral lawsuit alleges that Endologix's proprietary high density ePTFE graft material, which is used for the Powerlink® System, infringes on Bard Peripheral's "Prosthetic Vascular Graft" patent (U.S. Patent No. 6,436,135).
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
Our belief as to whether we will likely succeed or fail at a given task-and the consequences of winning or losing-directly affects the levels of neural effort put forth in movement-planning circuits in the human cortex, according to a new brain-imaging study by neuroscientists at the California Institute of Technology.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.